Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514572 | 0.81 | CNR2 (0.53) | CNR2GRM5MAOBF2F10 | |
| SCHEMBL5783107 | 0.81 | CNR2 (0.70) | CNR2GRM5 | |
| SCHEMBL24171803 | 0.81 | CNR2 (0.48) | CNR2GRM5MAOB | |
| SCHEMBL13606608 | 0.81 | FFAR1 (0.52) | CNR2 | |
| SCHEMBL4501777 | 0.76 | CNR2 (0.44) | CNR2GRM5F2F10PLG | |
| SCHEMBL2060134 | 0.76 | CNR2 (0.52) | CNR2MAOBF2F10PLG | |
| SCHEMBL936599 | 0.76 | ACACB (0.53) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL1077335 | 0.75 | CNR2 (0.42) | CNR2MAOBF2F10PLG | |
| SCHEMBL3923273 | 0.75 | CNR2 (0.51) | CNR2MAOB | |
| SCHEMBL13606609 | 0.75 | FFAR1 (0.49) | CNR2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1699775-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | Allergan, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CNR2 675/4885GABRA1 191/4885GABRA5 347/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | CNR2 590/4885GABRA1 665/4885GABRA5 555/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CNR2 675/4885GABRA1 191/4885GABRA5 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.